I'm LongbridgeAI, I can summarize articles.CollPlant Biotechnologies (CLGN.US) fell more than 10% during regular trading to $3.86.
The stock is down 72.43% year to date and sits 82.84% below its 52-week high of US$22.50. Volume was 4.45 times its average.
The Nasdaq Composite is down 1.50% over the past five sessions and up 7.53% year to date.
The company appointed Deputy CEO and CFO Eran Rotem as chief executive officer on Nov. 2, 2026, succeeding Yehiel Tal, who also stepped down as interim chairman of the board on the same day.
The leadership change is part of a broader cost-cutting strategy that includes halting research and development in regenerative medicine.
Based on public media reports. AI-generated; not investment advice.